Skip to content

Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.

Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02699476
Enrollment
60
Registered
2016-03-04
Start date
2016-02-29
Completion date
2017-12-31
Last updated
2016-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Concussion, Mild Cognitive Disorder, Traumatic Brain Injury

Keywords

NFL, veterans, cognitive training, TBI, concussion

Brief summary

The purpose of this study is to compare different combinations of cognitive training in retired professional football players and military veterans with a history of repeated concussions and persistent symptoms of impaired memory, concentration, attention, focus, or thinking.

Interventions

BEHAVIORALPsycho-Social Therapy
DEVICECognitive Behavioral Computer Training
BEHAVIORALInteractive Trainer-Subject Sessions
DEVICEActive Control Games

Sponsors

Brain & Body Health Foundation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* History of \>1 Mild TBI: post traumatic amnesia/confusion ≤ 24 hour immediately after injury; or loss of consciousness \<30 min confirmed by the Ohio State University TBI Identification Method-Short Form (OSU TBI-ID-SF). * Age 25-55 years * Minimum of 4 months post-injury * Adequate visual, auditory, sensory-motor function for training program. * Fluent in English * Persistent cognitive dysfunction confirmed by Ruff Neurobehavioral Inventory score of greater than 70 on any of the four cognitive scales (Attention, Memory, Language, Executive).

Exclusion criteria

* History of hypoxic event * Pre-existing significant neurological (e.g. MS) or psychiatric (e.g. schizophrenia, bi-polar) disorders. * Current illicit drug use or alcohol abuse * Unwilling or unable (e.g. language barrier) to participate * Hospitalization during study * Current Litigation * Positive on malingering test * Use of medications to enhance cognitive function (e.g. Ritalin) * Initial Glasgow Coma Score \< 13 or penetrating head injury * Subjects must not show suicidal ideation as measured by the Columbia-Suicide Severity Rating Scale. Subjects with a score of 4 or 5 (as recommended by the FDA for treatment trials) will be excluded and referred for appropriate treatment. * Subjects should not be enrolled in a concurrent TBI clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Composite performance score based on battery of neuropsychological tests of working memory, learning, memory, and executive function.within one week following treatment completionComposite performance score on neuropsychological battery based on four primary domains : learning, memory, working memory, and executive function.
Participant reported outcomeswithin one week following treatment completion.Measure of impact of program use on the patient's own view of their impairment and function.
Working/school statuswithin one week following treatment completion.Measure of participants' employment status, and the number of hours worked/volunteered/in-school per week.
Exercise-base assessmentswithin one week following treatment completion.Four sets of assessments that are closely modeled on study-related exercises in the auditory, visual, cognitive, and social-cognitive modules. These include auditory speed of processing, visual speed of processing, cognitive control speed of processing and face recognition, recall of unique faces, and emotional cue recognition.
Functional assessmentswithin one week following treatment completion.Timed instrumental activities of daily living (TIADL) and the Mayo-Portland Adaptability Inventory (MPAI-4) for sensitive directly observed performance and well-accepted clinical impression measures.

Countries

United States

Contacts

Primary ContactRobert W Van Boven, M.D., D.D.S.
brainbodyhealthfoundation@gmail.com512-981-5801
Backup ContactMark R Taylor, Ph.D.
mtaylormich@gmail.com586-945-6618

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026